NCT06548529 HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
| NCT ID | NCT06548529 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Cancer Hospital & Institute |
| Condition | HER2 Positive or Suspicious Positive Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-06-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
Eligibility Criteria
Inclusion Criteria: 1. Aged # 18 years old; ECOG 0 or 1; 2. Is unresectable or metastatic; 3. Patients with HER2 positive or suspicious positive tumors; 4. was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane; 5. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions; 6. Receives anti-HER2 ADC treatment 7. Life expectancy \> 3 months Exclusion Criteria: 1. Significant hepatic or renal dysfunction; 2. Is pregnant or ready to pregnant; 3. Cannot keep their states for half an hour; 4. Refused to join the clinical research; 5. Suffering from claustrophobia or other mental disorders; 6. Any other situation that researchers considered it unsuitable to participate in the trial.
Frequently Asked Questions
Who can join the NCT06548529 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying HER2 Positive or Suspicious Positive Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06548529 currently recruiting?
Yes, NCT06548529 is actively recruiting participants. Visit ClinicalTrials.gov or contact Peking University Cancer Hospital & Institute to inquire about joining.
Where is the NCT06548529 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06548529 clinical trial?
NCT06548529 is sponsored by Peking University Cancer Hospital & Institute. The trial plans to enroll 30 participants.